Journal
IMMUNOTHERAPY
Volume 12, Issue 12, Pages 903-920Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2020-0037
Keywords
biomarker; BRAF; CTLA4; DNA methylation; immune checkpoint; papillary thyroid carcinoma; PD-1; PD-L1; PD-L2
Categories
Funding
- BONFOR research funding program of the University of Bonn
- Qiagen
Ask authors/readers for more resources
Aim: We investigated DNA methylation patterns of immune checkpoint genes PD-1, PD-L1, PD-L2, CTLA4 and an adjacent long noncoding RNA in papillary thyroid carcinoma (PTC). Materials & methods: DNA methylation and mRNA expression were examined in PTCs. DNA methylation was correlated with mRNA expression, BRAF and RAS mutational status, and immune cell infiltration. Results: Inverse correlations between DNA methylation and mRNA expression were observed. Immune checkpoint expression correlated positively, and DNA methylation negatively, with immune cell infiltration. Higher DNA methylation levels accompanied by lower immune checkpoint expression were observed in RAS-mutated tumors. Conclusion: We suggest epigenetic regulation of immune checkpoints in PTC. Methylation was associated with BRAF and RAS mutation status. DNA methylation might be a promising biomarker candidate in the context of immunotherapies in PTC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available